Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

Inclusion Criteria: * Histologically diagnosed adenocarcinoma of the prostate. * Radiographically confirmed metastatic disease prior to patient enrollment. Metastatic disease can be confirmed based on conventional imaging (CT, MRI, nuclear medicine bone scan) or molecular imaging (fluciclovine-positron emission tomography (PET)/CT, prostate-specific membrane antigen (PSMA)-PET/CT, Choline-PET/CT etc). * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2. * Absolute neutrophil count (ANC) \>= 1.5 k/uL. * Platelets \>= 100 k/uL. * Hemoglobin \>= 9 g/dL. * Serum total bilirubin =\< 1.5 times upper limit of normal (ULN) OR direct bilirubin =\< ULN for subjects with total bilirubin \>= 1.5 x ULN. * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 x ULN OR =\< 4 x ULN for subjects with liver metastases. * Creatinine \< 1.5 x ULN OR * Creatinine clearance \> 50 mL/min for subject with creatinine levels \> 1.5 x ULN by Cockcroft-Gault formula or standard institutional practice. * Highly effective method of contraception for both male and female partners of subjects throughout the study and for at least 3 months after last study treatment administration if the risk of conception exists. * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines. * Recovery to baseline or =\< grade 1 Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 from toxicities r…